您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > PD 184161
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PD 184161
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PD 184161图片
CAS NO:212631-67-9
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
PD 184161 是一种口服活性 MEK 抑制剂。
Cas No.212631-67-9
化学名5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide
Canonical SMILESFC1=C(NC2=C(Cl)C=C(I)C=C2)C(C(NOCC3CC3)=O)=CC(Br)=C1F
分子式C17H13BrClF2IN2O2
分子量557.6
溶解度≤10mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 10-100 nM

PD 184161 is a MEK1/2 inhibitor.

The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions. One of these pathways, named Raf/MEK/ERK pathway, plays a key role in the regulation of cellular differentiation, growth, and proliferation. The modulation of this Raf/MEK/ERK pathway has been reported as a useful approach to treate proliferative disorders such as cancer.

In vitro: Previous study found that PD184161 could inhibit MEK activity in a time- and concentration-dependent manner, which was more effectively than PD098059 or U0126. Moreover, PD184161 could inhibit cell proliferation and induce apoptosis at concentrations of >or = 1.0 μM time- and concentration-dependently [1].

In vivo: Animal study showd that tumor xenograft P-ERK levels were significantly reduced 3 to 12 hours after an oral dose of PD184161. Contrarily, tumor xenograft P-ERK levels following long-term treatment of PD184161 were refractory to this signaling effect. PD184161 also significantly suppressed tumor engraftment and initial growth, however, established tumors were not significantly affected. In summary, PD184161 has antitumor effects in HCC in vivo that appear to correlate with suppression of MEK activity [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Klein, P. J.,Schmidt, C.M.,Wiesenauer, C.A., et al. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 8(1), 1-8 (2006).